Advancing Care for Pediatric Asthma: Targeting Type 2 Inflammation With Biologic Therapies

Please visit answersincme.com/860/014832-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Anne E. O'Donnell, MD; andPatrick Flume, MD. In this activity, experts in bronchiectasis discuss best practices for identifying, diagnosing, and treating CF and non-CF bronchiectasis. Upon completion of this activity, participants should be better able to:Distinguish between underlying causes of bronchiectasis that provide the rationale for targeting neutrophil inflammation. Outline recommended multidisciplinary strategies to promptly recognize and diagnose bronchiectasis. Describe the design and eligibility criteria of ongoing trials evaluating neutrophil-targeted therapies for bronchiectasis. This session is supported by Boehringer Ingelheim Pharmaceuticals, Inc. Exhibitors and supporters of NACFC include manufacturers of CF drugs, medical device companies, pharmacies, hospitals, and other related organizations. The Cystic Fibrosis Foundation does not support nor endorse the products or services of NACFC 2026 exhibitors and supporters.

Please visit answersincme.com/860/160204757-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Karen P. Acker, MD; and Donna Hallas, PhD, PPCNP-PC, CPNP, PMHS, FAANP, FAAN. In this activity, experts in RSV prevention discuss the latest evidence and practical strategies for implementing immunoprophylaxis and coordinating caregiver counseling across the care continuum. Upon completion of this activity, participants should be better able to: Discuss the rationale for RSV immunoprophylaxis for preventing RSV disease in early infancy. Integrate guideline recommendations into shared clinical decision-making for the prevention of RSV in infants. Outline the complementary roles of pre- and postnatal clinicians in coordinating RSV immunization counseling across the care continuum. Implement coordinated communication strategies to support caregiver decision-making about RSV prevention. This symposium is not sponsored, endorsed or accredited by the American Academy of Pediatrics.

Please visit answersincme.com/CJF860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Manuel Rodriguez-Justo, MBBCh, MSc, MD, FRCPath; and Elizabeth Smyth, MD, FRCP. In this activity, experts in oncology and pathology discuss the impact of claudin 18.2 (CLDN18.2) tests and treatments for patients with advanced gastric or gastroesophageal junction cancers. Upon completion of this activity, participants should be better able to: Describe the rationale for CLDN18.2 testing in patients with advanced gastric and gastroesophageal junction cancers (GC/GEJC); Review the potential clinical impact of emerging CLDN18.2-targeted antibody-drug conjugates (ADCs) for the treatment of GC/GEJC; and Outline evidence-based, emerging strategies to optimize outcomes in patients with advanced GC/GEJC.

Please visit answersincme.com/QRE860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Theresa W. Guilbert, MD, MS. In this activity, an expert in childhood asthma discusses the use of biologics for moderate to severe pediatric asthma. Upon completion of this activity, participants should be better able to: Identify the impact of type 2 inflammation on lung function in pediatric patients with asthma; Recognize best practices for incorporating biologics into the treatment of type 2 inflammatory pediatric asthma; and Review the clinical profiles of biologic therapies for type 2 inflammatory asthma in pediatric patients. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/MSM860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Ritu Salani, MD; and Courtney Arn, CNP. In this activity, experts in gynecological oncology discuss antibody-drug conjugates (ADCs) in ovarian, cervical, and endometrial cancers. Upon completion of this activity, participants should be better able to: Describe the rationale for using ADCs in previously treated patients with gynecologic cancers; Assess the safety and tolerability evidence for approved ADC therapies in gynecologic cancers; Formulate management strategies for adverse events associated with ADC treatment of ovarian, cervical, and endometrial cancers; and Outline patient-centered approaches to facilitate adherence with ADC therapy.

Please visit answersincme.com/FSP860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Jay N. Yepuri, MD, MS, FACG, FTSGE. In this activity, an expert in gastroenterology discusses molecular prognostics tests that predict the risk of progression from Barrett’s esophagus (BE) to esophageal adenocarcinoma (EAC). Upon completion of this activity, participants should be better able to: Describe the limitations of traditional approaches to predicting risk of progression to EAC for patients with BE; Review the evolving role of advanced molecular prognostic tests in assessing risk of progression to EAC in patients with BE; and Outline multidisciplinary strategies to integrate advanced molecular prognostic tests into the management of patients with BE.

Please visit answersincme.com/WAY860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Elizabeth O'Donnell, MD. In this activity, an expert in multi-cancer early detection (MCED) discusses strategies to apply MCED testing into everyday clinical practice. Upon completion of this activity, participants should be better able to: Discuss the benefits and risks of MCED testing; and Outline patient-centered strategies to appropriately incorporate MCED testing into the primary care setting.

Please visit answersincme.com/BVK860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Jesus E. Pina-Garza, MD. In this activity, an expert in epilepsy discusses recognizing seizure emergencies, selecting appropriate rescue treatments and routes of administration, and developing individualized seizure action plans. Upon completion of this activity, participants should be better able to: Define seizure emergencies based on expert consensus to support accurate treatment decisions; Evaluate approved therapeutic approaches for the management of seizure clusters in the home/community setting; and Identify strategies to support the timely use of acute seizure medications through patient-centered seizure action plans.

Please visit answersincme.com/860/cvdprostate-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Michael Cookson, MD; Alicia Morgans, MD, MPH; and Avirup Guha, MD, MBBS, MPH, FAHA, FACC, FESC, FICOS. In this activity, experts in prostate cancer discuss cardiovascular risk in patients receiving androgen-deprivation therapy (ADT). Upon completion of this activity, participants should be better able to: Evaluate the impacts of prostate cancer and ADT on cardiovascular risk; Translate the latest research for cardiovascular management of patients on ADT to clinical practice; and Design personalized treatment approaches to optimize ADT across treatment settings.

Please visit answersincme.com/NHB860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Zev Wainberg, MD. In this activity, an expert in oncology discusses the use of TROP2-directed antibody-drug conjugates (ADCs) across solid tumors. Upon completion of this activity, participants should be better able to: Review the rationale for targeting TROP2 with antibody-drug conjugates (ADCs) across tumor stages and settings; Evaluate the clinical profiles of available and emerging TROP-targeting ADCs across tumor stages and settings; and Apply evidence-based strategies to recognize and monitor treatment-related adverse events (TRAEs) associated with ADCs.